BioRegenx (BRGX) Stock Statistics & Valuation Metrics
Total Valuation
BioRegenx has a market cap or net worth of $194.31K. The enterprise value is $10.18T.
- Market Cap
- $194.31K
- Enterprise Value
- $10.18T
Share Statistics
BioRegenx has 971,575,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 971,575,200
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
BioRegenx’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is 31.98%.
- Return on Equity (ROE)
- 0.34
- Return on Assets (ROA)
- -3.76
- Return on Invested Capital (ROIC)
- 31.98%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 309.09K
- Profits Per Employee
- -257.26K
- Employee Count
- 6
- Asset Turnover
- 4.51
- Inventory Turnover
- 3.28
Valuation Ratios
The current PE Ratio of BioRegenx is -0.15. BioRegenx’s PEG ratio is -0.00.
- PE Ratio
- -0.15
- PS Ratio
- 0.11
- PB Ratio
- -0.04
- Price to FCF
- 10.31
- Price to Operating Cash Flow
- 6.95
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, BioRegenx had revenue of 1.85M and earned -1.54M in profits. Earnings per share was -0.00.
- Revenue
- 1.85M
- Gross Profit
- 1.50M
- Operating Income
- -518.99K
- Pretax Income
- -1.54M
- Net Income
- -1.54M
- EBITDA
- -443.92K
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was 27.91K and capital expenditures -9,057, giving a free cash flow of 18.85K billion.
- Operating Cash Flow
- 27.91K
- Free Cash Flow
- 18.85K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
BioRegenx pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.70%
- Earnings Yield
- -672.21%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
BioRegenx as a current ratio of 0.06, with Debt / Equity ratio of -48.81%
- Current Ratio
- 0.06
- Quick Ratio
- 0.04
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- -4.83
- Interest Coverage Ratio
- 1.73
Taxes
In the past 12 months, BioRegenx has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
BioRegenx EV to EBITDA ratio is -6.85, with an EV/FCF ratio of 122.75.
- EV to Sales
- 1.31
- EV to EBITDA
- -6.85
- EV to Free Cash Flow
- 122.75
- EV to Operating Cash Flow
- 82.92
Balance Sheet
BioRegenx has $45.81K in cash and marketable securities with $2.17M in debt, giving a net cash position of -$2.12M billion.
- Cash & Marketable Securities
- $45.81K
- Total Debt
- $2.17M
- Net Cash
- -$2.12M
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 81.90%, with operating margin of -21.30%, and net profit margin of -73.80%.
- Gross Margin
- 81.90%
- Operating Margin
- -21.30%
- Pretax Margin
- -73.81%
- Net Profit Margin
- -73.80%
- EBITDA Margin
- -19.14%
- EBIT Margin
- -21.30%
Analyst Forecast
The average price target for BioRegenx is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- -23.43%
- EPS Growth Forecast
- 93.36%
